Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05258721Phase 2Completed

Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP

Role: lead

NCT04409873Phase 2Terminated

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

Role: collaborator

NCT04838054Phase 4Completed

The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis

Role: lead

NCT03160560Not ApplicableCompleted

Controlling Oral Malodor by ClōSYS® Oral Rinse

Role: lead

NCT03160573Not ApplicableCompleted

Controlling Oral Malodor by ClōSYS Oral Rinse

Role: lead

All 5 trials loaded